Therapy News and Research

RSS

Two Cedars-Sinai physicians to receive ACC Distinguished Scientist Award

Two physicians from the Cedars-Sinai Heart Institute will receive the American College of Cardiology's highest honors for scientific research and clinical care during the organization's upcoming annual scientific meeting in Chicago.

20 Mar 2012

Researchers identify Wnt pathway as new target for scleroderma therapy

A genetic pathway previously known for its role in embryonic development and cancer has been identified as a target for systemic sclerosis, or scleroderma, therapy.

20 Mar 2012

New three-step process for DMD newborn screening

Investigators at Nationwide Children's Hospital, working with the DNA Sequencing Core Facility at the University of Utah, have developed an approach to newborn screening (NBS) for the life-threatening genetic disorder, Duchenne muscular dystrophy (DMD) and potentially other muscular dystrophies.

20 Mar 2012

Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.

20 Mar 2012

AIDS survey preliminary data show stagnation in Uganda's HIV prevalence, need for improved prevention strategies, experts say

A preliminary report on the Uganda AIDS Indicator Survey, conducted by the Ministry of Health, shows the country's "HIV prevalence rate has stagnated over the last 10 years, and the number of people infected with HIV has risen from 1.8 million people to 2.3 million today," the Observer writes.

20 Mar 2012

Groundbreaking cystic fibrosis clinical trial to proceed after renewed funding

The team of scientists based in Edinburgh, Oxford and London were developing a treatment which involves putting genes into the lungs of patients suffering the fatal, inherited wasting disease, passed early clinical trials in 2010. But the recession badly affected the Cystic Fibrosis Trust, the charity that had funded the programme, and work had to stop last year just as the consortium was closing in on its goal.

19 Mar 2012

$Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015$

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. hematologist-oncologists and managed care organization (MCO) pharmacy directors agree that survival effect is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in patients with chronic myeloid leukemia who have failed first-line tyrosine kinase inhibitor therapy.

19 Mar 2012

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

Merz launches new, once daily Mederma Advanced Scar Gel

Mederma, the #1 doctor-and pharmacist-recommended brand for scars for over a decade, announced today the introduction of Mederma Advanced Scar Gel, which reduces the overall appearance of scars caused by injury, acne, surgery or burns with just one daily application. Mederma Advanced Scar Gel contains Cepalin, the same proprietary botanical extract derived from onions used in all Mederma® scar products and stretch marks therapy.

19 Mar 2012

BSD-500 Hyperthermia System installed at Fort Belvoir Community Hospital

BSD Medical Corporation announced today the purchase, installation and acceptance of a BSD-500 Hyperthermia System (BSD-500) by Fort Belvoir Community Hospital (Fort Belvoir).

19 Mar 2012

IOB, Delcath to launch CHEMOSAT system for Spanish cancer patients

Delcath Systems, Inc. announced today that the Company has entered into an initial launch and training agreement for the Delcath Hepatic CHEMOSAT Delivery system with the Instituto Oncologico Baselga (IOB), Grupo Quiron—a private hospital located in Barcelona, Spain.

19 Mar 2012

Prostate Center of Academic Urology receives accreditation from ACR, ASTRO

The Prostate Center of Academic Urology has been awarded a three-year term of accreditation in radiation oncology from the American College of Radiology (ACR) and The American Society for Radiation Oncology.

19 Mar 2012

Exercise can induce sexual pleasure, female orgasm

Findings from a first-of-its-kind study by Indiana University researchers confirm anecdotal evidence that exercise -- absent sex or fantasies -- can lead to female orgasm.

19 Mar 2012

Researchers show how errant form of LYP can disrupt the immune system

Autoimmune diseases, such as Type I diabetes and rheumatoid arthritis, are caused by an immune system gone haywire, where the body's defense system assaults and destroys healthy tissues. A mutant form of a protein called LYP has been implicated in multiple autoimmune diseases, but the precise molecular pathway involved has been unknown.

19 Mar 2012

East Asian BIM gene variant contributes to drug resistance in cancer

A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.

19 Mar 2012

Study reveals how Bdnf gene mutation contributes to severe obesity

Researchers at Georgetown University Medical Center have revealed how a mutation in a single gene is responsible for the inability of neurons to effectively pass along appetite suppressing signals from the body to the right place in the brain. What results is obesity caused by a voracious appetite.

19 Mar 2012

Scientist generates mutant version of IL-2 protein to treat advanced cancers

The utility of a naturally occurring protein given, sometimes to great effect, as a drug to treat advanced cancers is limited by the severe side effects it sometimes causes. But a Stanford University School of Medicine scientist has generated a mutant version of the protein whose modified shape renders it substantially more potent than the natural protein while reducing its toxicity.

19 Mar 2012